Something really funny, for me at least.
'The Australian’s Criterion column last week reported that Sirtex had returned to favour after releasing some positive results of its liver cancer trial and a 22 per cent lift in its global SIR-Sphere sales in the first 10 months of the financial year.'
I recall reading Criterion stating to 'leave alone', only last week. Maybe I misunderstood his value proposition. I know one has to be selective with HC posts, but I thought the big Aussie was a little more 'true'.
Sirtex in Bayer’s sights, page-2
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.27M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 17.5¢ | $1.602K | 9.154K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 3847679 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 2509481 | 36 |
View Market Depth
| Last trade - 15.19pm 23/08/2024 (20 minute delay) ? |
| SRX (ASX) Chart |